Market revenue in 2024 | USD 346.5 million |
Market revenue in 2030 | USD 259.2 million |
Growth rate | -5% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.57% in 2024. Horizon Databook has segmented the Italy anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
In Italy, the demand for anti-VEGF therapeutics is increasing due to the disease burden of indications such as age-related macular degeneration, diabetic retinopathies, among others. s. According to the Global Burden of Diseases (GBD) database, around 214,684 people were found to be affected by age-related macular degeneration in 2019 from 208,632 in 2018.
Increase in government initiatives to address unmet medical needs, such as inclusion of anti-VEGF therapeutics for reimbursement, is expected to contribute to market growth. In January 2021, Italian Medicines Agency (AIFA) announced the adoption of Note 98 for the disbursement of total expenses.
Drugs are granted reimbursement approval by local health authorities of the concerned region. Full coverage is available for hospital drugs. The Italian Medicines Agency (AIFA) is the concerned regulatory authority that extends access to drugs that have not been granted a marketing authorization through the preauthorization program.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Italy anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account